News

FDA Approves Second Meningitis B Vaccine

Novartis announced that the Food and Drug Administration (FDA) has granted accelerated approval of Bexsero (meningococcal group B vaccine [recombinant, adsorbed]) for active immunization to prevent invasive meningitis B in patients aged 10 to 25 years.

New Fixed-Dose Combo Tabs for Hypertension Approved

Symplmed announced that the Food and Drug Administration (FDA) has approved Prestalia (perindopril arginine and amlodipine) tablets for the treatment of hypertension in patients whose blood pressure is uncontrolled on monotherapy.

Natpara Injection Approved for Hypocalcemia

The Food and Drug Administration (FDA) has approved Natpara (parathyroid hormone; NPS Pharmaceuticals) for injection as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

HPV Vaccine Often Not Received at Recommended Age

Only about half of American girls begin receiving the human papillomavirus (HPV) vaccine at the recommended age.

AAP Urges Measles Vaccine for Children

With the latest measles outbreak, the American Academy of Pediatrics (AAP) recommended that all parents vaccinate their children against measles.

Eczema May Carry Higher Cardiovascular Risk

Adults with eczema may have an increased risk of heart disease and stroke, possibly due to risk factors such as obesity and diabetes.

Age's Effect on Outcome of Revision Cochlear Implantation Assessed

Age at revision cochlear implantation does not impact post-revision speech perception performance.

Lipid Changes with Some RA Drugs Seen in Study

For patients with rheumatoid arthritis (RA), moderate changes in lipids are observed after treatment with tocilizumab or tofacitinib.

New CDC Report on Influenza, Plus a Quiz for Clinicians

The Centers for Disease Control and Prevention (CDC) has issued a new surveillance report for the week ending January 17, 2015 on influenza-related mortality, hospitalizations, and outpatient illness, as well as the geographic spread.

Labeling Update for Xarelto

The Food and Drug Administration (FDA) announced that it has approved an update to the prescribing information for Xarelto (rivaroxaban; Janssen).